Drug Trial Radar · NCT02988089
Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment
Last checked: Nov 19, 2026Latest source record: Apr 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
480
Planned (sponsor's estimate)
Start
Apr 20, 2017
Primary completion
Sep 2017
Study completion Sep 2017
Sponsor
- Lead sponsor
- Shandong UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shandong Provincial Hospital; General Hospital of Jinan Military Region; Binzhou People's Hospital; Liaocheng People's Hospital
- First posted
- Dec 9, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Helicobacter pylori (H. pylori), which infects about 50% of the global population, has been recognized as a main risk factor of multiple gastric pathologies, especially non-cardiac gastric cancer. Strongly evidence supports that H. pylori eradication is an effective approach to reduce the incidence of those pathologies.
Conditions
- Helicobacter Pylori Infection
- Antimicrobial Susceptibility Testing
Interventions
Clarithromycin susceptibility dependant strategyDrug
Patients in this group will receive a 14-day bismuth-based quadruple regimen to eradicate H. pylori. Antimicrobial susceptibility testing (AST) will be used to test the susceptibility of clarithromycin. If clarithromycin is susceptible, amoxicillin 1 g b.i.d and clarithromycin 500 mg b.i.d will be chosen; If clarithromycin is resistant, amoxicillin 1 g bid and furazolidone 100 mg b.i.d will be chosen.
2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline )Drug
Patients in this group will receive a a 14-day bismuth-based quadruple regimen to eradicate H. pylori. The regimen is consist of a PPI, Colloidal Bismuth Pectin and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
proton pump inhibitor (PPI) and Colloidal Bismuth PectinDrug
all patients need these two drugs.
amoxicillin and clarithromycin or amoxicillin and furazolidoneDrug
patients in the 6 antibiotics dependant group will use these intervention.
amoxicillin and furazolidone or amoxicillin and tetracyclineDrug
salvage therapy for negative culture when the results of culture are negative
amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and LevofloxacinDrug
salvage therapy for failed eradication if failed with AST guided eradication therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Eradication rates in 2 groupsTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Gastroenterology, Qilu Hospital, Shandong University
Ji'nan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.